Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

Summary

The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do not have asthma. Patients will be recruited from and followed in SCD clinics at participating sites. The primary endpoint will be a reduction in sVCAM level of 20% or more in comparison to placebo.

Timeline

Start

2018-11-29

Primary completion

2023-05-31

Completion

2023-05-31

Drugs

Indications